CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...